Kuros BioSciences B.V.
5
2
2
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 85/100
20.0%
1 terminated/withdrawn out of 5 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion
Role: collaborator
MagnetOs Flex Matrix Compared to Trinity Elite Mixed With Local Autograft in Patients Undergoing up to Four-level Instrumented Posterolateral Fusion
Role: collaborator
MagnetOs™ Granules vs. Autograft in Instrumented Posterolateral Spinal Fusion
Role: collaborator
Post Marketing Clinical Follow up Study for MagnetOs Putty in Patients With Degenerative Disc Disease
Role: collaborator
KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion
Role: collaborator
All 5 trials loaded